Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
China Resources Sanjiu Medical & PharmaceuticalFinance

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange
IPOVigonvita Life Sciences

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study
CancerImmunophage Biotech

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study

Henan Lingrui Yingu Pharma Anticholinergic Drug
Lingrui PharmaceuticalSHA: 600285

Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million

Show More